Treatment for Candida glabrata After Failed Nystatin Therapy
Since nystatin has already failed after 14-24 days of treatment, the next step is intravaginal boric acid 600 mg daily for 14 days, which is the recommended first-line therapy for C. glabrata vulvovaginitis unresponsive to azoles and nystatin. 1
Clinical Context and Reasoning
This 88-year-old patient with a pessary represents a complicated vulvovaginal candidiasis case due to:
- Non-albicans species (C. glabrata)
- Presence of foreign body (pessary)
- Failed initial therapy with nystatin
- Advanced age
C. glabrata accounts for 10-20% of recurrent vulvovaginal candidiasis cases and is inherently less susceptible to conventional azole therapies compared to C. albicans 2, 1. The pessary creates a persistent nidus for infection and biofilm formation.
Treatment Algorithm After Nystatin Failure
First-Line: Boric Acid
- Intravaginal boric acid 600 mg in gelatin capsule daily for 14 days 1
- Clinical and mycologic eradication rates: approximately 70% 2
- Must be compounded by pharmacy
- Studies show 64-71% success in symptomatic women with C. glabrata 3
- Critical caveat: Boric acid is toxic if ingested; counsel patient on proper vaginal administration only
Second-Line Options if Boric Acid Fails
Topical 17% flucytosine cream (alone or combined with 3% amphotericin B cream) daily for 14 days 1
Repeat nystatin course - Though already attempted, the guidelines list nystatin intravaginal suppositories 100,000 units daily for 14 days as an alternative 1. However, given prior failure, this is less advisable.
Essential Concurrent Management
Pessary Management
- Remove and clean pessary during treatment - The pessary must be disinfected or temporarily removed during antifungal therapy to eliminate the biofilm reservoir
- Consider pessary removal schedule that allows vaginal tissue recovery
- Evaluate if pessary is still medically necessary
Confirm Diagnosis
- Obtain vaginal culture to confirm C. glabrata and rule out mixed infection 1
- Consider antifungal susceptibility testing given treatment failure 1
- Wet mount with KOH to confirm active infection vs. colonization 1
Important Clinical Pitfalls
Do not use oral fluconazole - C. glabrata has reduced susceptibility to all azoles, including fluconazole and voriconazole 1, 4. Therapy with azoles is "frequently unsuccessful" for C. glabrata 1, 4.
Distinguish infection from colonization - The most critical decision is whether C. glabrata represents true infection requiring treatment versus colonization in a patient with other pathology 1. Only treat if symptomatic with confirmed yeast on microscopy.
Age considerations - At 88 years old, this patient may have vaginal atrophy contributing to symptoms. Ensure symptoms are truly from candidiasis and not atrophic vaginitis.
If Recurrence Occurs
For recurring C. glabrata infection after successful treatment:
- Consider maintenance therapy with boric acid (dosing frequency not well-established in guidelines, but expert consensus suggests 1-3 times weekly) 5
- Re-evaluate pessary necessity and fit
- Screen for diabetes, immunosuppression, or other predisposing factors
- Some experts use individualized degressive regimens to find the lowest effective maintenance dose 6
Contraindications and Safety
Boric acid should not be used during pregnancy 5. At age 88, pregnancy is not a concern. Local side effects are uncommon with boric acid 3, 7. The patient should be counseled that boric acid is for vaginal use only and is toxic if swallowed.